Skip to content

Gomdori Medical

Evidence-Based Medical Education by gomdori, MD

MENU
  • Home
  • Gastroenterology
  • Procedures
  • Critical Care
  • More Specialties
    • Cardiovascular Medicine
    • Respiratory Medicine
    • Nephrology & Renal Care
    • Hematology
    • Oncology
    • Endocrinology
    • Allergy & Immunology
    • Infectious Diseases
    • Rheumatology
  • Tools
  • About gomdori Medical
  • Conference News
  • Clinical Library
Home » Aortic Stenosis: Diagnosis, Staging, and Management

Aortic Stenosis: Diagnosis, Staging, and Management

Posted on April 12, 2026November 12, 2026 by Gomdori
gomdori Medical · Clinical Guideline
Aortic Stenosis: Diagnosis, Staging, and Management
Clinical Guideline gomdorimedical.com
Home › Guidelines › Aortic Stenosis: Diagnosis, Staging, and Management
gomdori Medical
Clinical Guideline

Aortic Stenosis: Diagnosis, Staging, and Management

April 12, 2026 gomdori 22 min read AHA / ACC / ESC Valvular Heart Disease
Referenced Clinical Guidelines
ACC
American College of Cardiology
Clinical practice guidelines in cardiology
ESC
European Society of Cardiology
European clinical practice guidelines in cardiology
Executive Summary

Aortic stenosis is the most common valvular heart disease in the developed world, driven by progressive calcific degeneration of the aortic valve that produces left ventricular pressure overload, concentric hypertrophy, and ultimately heart failure. Diagnosis hinges on transthoracic echocardiography with severity graded by aortic valve area (≤1.0 cm2 = severe), mean transvalvular gradient (≥40 mmHg), and peak aortic jet velocity (≥4.0 m/s). Once symptoms develop — exertional dyspnea, syncope, or angina — the average survival without intervention drops below two years, making timely referral for surgical aortic valve replacement (SAVR) or transcatheter aortic valve replacement (TAVR) the definitive management. No medical therapy slows disease progression; pharmacologic management is limited to blood pressure optimization with cautious use of ACE inhibitors and diuretics, while avoiding excessive preload reduction.

3.4%
Prevalence age ≥75
95%
TAVR 1-yr survival (low risk)
50%
2-yr mortality if symptomatic untreated
1-2%
Annual sudden death risk (severe AS)
Contents
  1. Pathophysiology
    • Valve calcification cascade
    • LVH and diastolic dysfunction
  2. Diagnostic Protocol
    • AHA/ACC staging A–D
    • Low-flow low-gradient AS
  3. Treatment Algorithm
    • SAVR vs TAVR decision
    • Balloon valvuloplasty
  4. Monitoring & Surveillance
  5. Clinical Commentary
  6. Practice Insights
    • What drives AS timing and modality choices
  7. FAQ
1

Pathophysiology

Aortic stenosis results from progressive calcific degeneration of the aortic valve leaflets, producing a fixed obstruction to left ventricular outflow that generates a chronic pressure overload on the left ventricle. The process begins with endothelial disruption on the aortic surface of the valve leaflets, triggering lipid infiltration, oxidative stress, and an inflammatory cascade that mirrors early atherosclerosis. However, unlike coronary artery disease, statin therapy does not slow this progression because the dominant pathologic driver shifts from lipid deposition to an osteoblast-mediated active calcification process involving bone morphogenetic protein-2 (BMP-2), Wnt/beta-catenin signaling, and RUNX2-driven mineralization of the valve interstitial cells. In patients with bicuspid aortic valves, turbulent flow across the congenitally abnormal leaflets accelerates this process by one to two decades compared to tricuspid valves.

Core Mechanism
Osteoblastic transformation of valve interstitial cells with progressive leaflet calcification, fibrosis, and commissural fusion leading to reduced aortic valve area and fixed LV outflow obstruction
Key Pathway
Endothelial injury → LDL/Lp(a) infiltration → oxidative modification → macrophage/T-cell inflammation → BMP-2/Wnt/RUNX2 activation → osteoblastic differentiation → hydroxyapatite deposition → leaflet stiffening
Genetic Factors
LPA gene variants (elevated lipoprotein(a)), NOTCH1 mutations (bicuspid aortic valve), PALMD/TEX41 loci associated with aortic valve calcification; bicuspid aortic valve present in 1-2% of population with 50% heritability
Risk Factors
MODIFIABLE: hypertension, hyperlipidemia, smoking, chronic kidney disease, diabetes, metabolic syndrome | NON-MODIFIABLE: age >65, male sex, bicuspid aortic valve, rheumatic heart disease, radiation exposure
Biomarkers
BNP/NT-proBNP (>300 pg/mL suggests decompensation), high-sensitivity troponin (myocardial fibrosis), lipoprotein(a) >50 mg/dL (accelerated calcification), CT aortic valve calcium score (Agatston: men >3000, women >1600 = likely severe AS)

The hemodynamic consequence of progressive valve narrowing is a steadily increasing pressure gradient between the left ventricle and the aorta. The left ventricle compensates through concentric hypertrophy, which maintains wall stress according to the law of Laplace by increasing wall thickness proportional to the rising intracavitary pressure. This adaptation preserves ejection fraction for years to decades but comes at a cost: the thickened myocardium develops impaired relaxation and reduced compliance, causing diastolic dysfunction with elevated filling pressures that produce exertional dyspnea even before systolic function declines. Over time, ongoing pressure overload overwhelms compensatory mechanisms, myocyte apoptosis and interstitial fibrosis develop, the ventricle transitions from concentric hypertrophy to eccentric remodeling and chamber dilation, and ejection fraction falls. At this decompensated stage, cardiac output becomes fixed and inadequate for exercise, producing the classic triad of heart failure symptoms, exertional syncope from inability to augment output, and angina from supply-demand mismatch in the hypertrophied ventricle. The onset of any of these symptoms marks a dramatic inflection in prognosis, with average survival dropping to two to three years for angina, two years for syncope, and one to two years for heart failure without intervention.

Aortic Stenosis Pathophysiology Cascade Flowchart depicting the pathologic progression from endothelial injury and valve calcification through pressure overload, left ventricular hypertrophy, diastolic dysfunction, and ultimately heart failure with symptom onset. Endothelial Injury + LDL/Lp(a) Infiltration Inflammatory Cascade + Osteoblastic Transformation (BMP-2 / RUNX2) Progressive Leaflet Calcification AVA narrows: 3-4 cm2 → <1.0 cm2 LV Pressure Overload → Concentric LVH Compensated phase: preserved EF, diastolic dysfunction Decompensation → HF / Syncope / Angina Survival: HF 1-2yr | Syncope 2-3yr | Angina 3-5yr Bicuspid valve: accelerates 1-2 decades Statins: NO effect on AS progression YEARS DECADES
2

Diagnostic Protocol

The diagnosis of aortic stenosis begins with clinical suspicion based on the classic systolic crescendo-decrescendo murmur radiating to the carotid arteries, heard best at the right upper sternal border with the patient sitting upright and leaning forward during end-expiration. Key physical examination findings that increase specificity include a late-peaking murmur, a diminished and delayed carotid upstroke (pulsus parvus et tardus), a single or absent S2 (loss of the aortic component), and a sustained apical impulse. However, physical examination alone cannot reliably grade severity. The cornerstone diagnostic tool is transthoracic echocardiography (TTE), which provides a comprehensive assessment of valve morphology, hemodynamic severity, and left ventricular response. Every patient with a new systolic murmur of at least Grade 2 intensity and every patient presenting with unexplained dyspnea, syncope, or angina over age 65 should receive a TTE to evaluate for aortic stenosis. Serial echocardiographic surveillance is then used to track disease progression and guide the timing of intervention.

AHA/ACC Staging and Severity Classification

AHA/ACC Staging System for Aortic Stenosis (Stages A through D)
StageDefinitionHemodynamic CriteriaClinical Action
Stage A — At RiskBicuspid valve, sclerosis, or rheumatic changes without hemodynamic obstructionVmax <2.0 m/s, normal AVARisk factor modification; TTE q3-5 years
Stage B — ProgressiveMild to moderate valve obstruction; asymptomaticMild: Vmax 2.0-2.9 m/s, AVA 1.5-2.0 cm2; Moderate: Vmax 3.0-3.9 m/s, AVA 1.0-1.5 cm2, mean gradient 20-39 mmHgMild: TTE q3-5yr; Moderate: TTE q1-2yr
Stage C — Severe AsymptomaticSevere valve obstruction; no symptoms. C1 = LVEF ≥50%; C2 = LVEF <50%Vmax ≥4.0 m/s, mean gradient ≥40 mmHg, AVA ≤1.0 cm2 (indexed ≤0.6 cm2/m2)C1: TTE q6-12mo, exercise testing; C2: AVR recommended
Stage D — Symptomatic SevereSevere AS with symptoms (dyspnea, syncope, angina). D1 = high gradient; D2 = low-flow low-gradient with reduced EF; D3 = paradoxical low-flow low-gradient with preserved EFD1: Vmax ≥4.0, MG ≥40; D2: AVA ≤1.0, MG <40, EF <50%; D3: AVA ≤1.0, MG <40, SVi <35 mL/m2, EF ≥50%AVR indicated for all D substages; D2 requires dobutamine stress echo to confirm true severe AS

Echocardiographic Severity Grading

Hemodynamic severity grading of aortic stenosis by echocardiography
ParameterMildModerateSevere
Peak aortic jet velocity (Vmax)2.0–2.9 m/s3.0–3.9 m/s≥4.0 m/s
Mean transvalvular gradient<20 mmHg20–39 mmHg≥40 mmHg
Aortic valve area (AVA)>1.5 cm21.0–1.5 cm2≤1.0 cm2
Indexed AVA (AVAi)>0.85 cm2/m20.6–0.85 cm2/m2≤0.6 cm2/m2
Velocity ratio (DI)>0.500.25–0.50<0.25

Low-flow low-gradient severe AS (Stage D2 and D3) presents a diagnostic challenge because the reduced stroke volume generates a mean gradient below 40 mmHg despite a severely narrowed valve. In classical low-flow low-gradient AS (D2), reduced LVEF produces low transvalvular flow. A low-dose dobutamine stress echocardiogram is essential to differentiate true severe AS (valve area remains ≤1.0 cm2 with augmented flow) from pseudo-severe AS (valve area increases beyond 1.0 cm2 as flow improves). Paradoxical low-flow low-gradient AS (D3) occurs in patients with preserved ejection fraction but a small, hypertrophied, restrictive left ventricle generating a stroke volume index below 35 mL/m2. CT aortic valve calcium scoring is particularly useful in this scenario: a score exceeding 3000 Agatston units in men or 1600 in women confirms severe AS independent of hemodynamic measurements. Grade B

Diagnostic Workup

Recommended diagnostic tests with clinical utility
TestRationale / What It ShowsSensitivitySpecificity
Transthoracic echocardiography (TTE)Primary diagnostic tool: valve morphology, AVA by continuity equation, mean gradient, Vmax, LVEF, LV wall thickness, diastolic function95-98%95-98%
CT aortic valve calcium scoreQuantifies calcification burden; confirms severity when hemodynamics are discordant (low-flow low-gradient); men >3000, women >1600 Agatston = severe86-93%80-92%
Low-dose dobutamine stress echoDifferentiates true severe from pseudo-severe AS in D2 (low-flow low-gradient reduced EF); assesses contractile reserve85-92%80-88%
Cardiac catheterization (invasive hemodynamics)Direct measurement of transvalvular gradient via pullback; used when non-invasive data are discordant or inadequate90-95%92-96%
BNP / NT-proBNPElevated levels indicate hemodynamic decompensation and predict symptom onset; useful for risk stratification in asymptomatic severe AS68-82%70-85%
Exercise stress testingUnmasks symptoms in Stage C1 patients who report being asymptomatic; a fall in systolic BP of ≥10 mmHg from baseline to peak exercise predicts symptom onset, while management of a lack of appropriate BP rise is less clear60-70%85-90%
Aortic Stenosis Severity Staging and Mortality Risk Horizontal bar chart displaying four stages of aortic stenosis (A through D) with corresponding aortic valve area ranges, mean gradient thresholds, and associated annual mortality risk percentages. AS Severity Stages: AVA & Annual Mortality Stage A: At Risk Stage B: Progressive Stage C: Severe Asx Stage D: Symptomatic AVA >2.0 cm2 | <1% annual mortality AVA 1.0-2.0 cm2 | 1-3% annual mortality AVA ≤1.0 cm2 | 3-6%/yr AVA ≤1.0 + Sx | 25-50%/yr Bar length proportional to annual mortality risk. Vmax thresholds: mild <3.0 | moderate 3.0-3.9 | severe ≥4.0 m/s Mean gradient thresholds: mild <20 | moderate 20-39 | severe ≥40 mmHg

Differential Diagnosis

Key conditions to differentiate from aortic stenosis
ConditionDistinguishing FeatureKey Workup
Hypertrophic obstructive cardiomyopathy (HOCM)Dynamic LVOT obstruction worsens with Valsalva and standing; systolic anterior motion of the mitral valve on echo; no valve calcificationTTE with provocative maneuvers; genetic testing for sarcomere mutations
Subaortic membrane (discrete subaortic stenosis)Fixed LVOT obstruction below the aortic valve; thin membrane visible on parasternal long-axis view; early diastolic murmur from secondary aortic regurgitationTTE with zoom on LVOT; TEE for membrane delineation; CT/MRI
Supravalvular aortic stenosisObstruction above the sinotubular junction; associated with Williams syndrome; right arm systolic pressure higher than left (Coanda effect)TTE with suprasternal notch view; CT aortography; genetic testing for elastin deletion
Aortic sclerosis (without stenosis)Valve thickening and calcification without hemodynamic obstruction; Vmax <2.0 m/s; normal AVA; still carries increased cardiovascular event riskTTE confirming Vmax <2.0 m/s and no gradient; serial monitoring q3-5 years
Mitral regurgitationHolosystolic rather than crescendo-decrescendo; radiates to axilla not carotids; blowing quality; primary MR shows flail/prolapse on echoTTE with color Doppler evaluation of mitral valve apparatus
3

Treatment Algorithm

The treatment of aortic stenosis follows a stage-dependent approach with one overarching principle: no medical therapy alters disease progression, and aortic valve replacement is the only intervention that improves survival in symptomatic severe AS. For asymptomatic patients (Stages A and B), management focuses on cardiovascular risk factor optimization and serial echocardiographic surveillance. The critical decision point occurs when patients reach Stage C (severe asymptomatic) or Stage D (symptomatic severe), where the timing and modality of valve intervention — surgical AVR versus transcatheter AVR — are determined by a multidisciplinary heart team evaluation incorporating surgical risk scores, anatomic suitability, life expectancy, patient preferences, and institutional expertise. Medical therapy serves only as a bridge to intervention or for palliation in patients who are not candidates for any form of valve replacement.

1
Step 1 — Medical Optimization and Surveillance (Stage A-C1)

All patients with aortic stenosis receive aggressive cardiovascular risk factor management. Hypertension is treated to target, using ACE inhibitors or ARBs as first-line agents. Cautious diuresis for volume overload symptoms is appropriate, but avoid excessive preload reduction in patients with fixed outflow obstruction. There is no role for statin therapy specifically for slowing AS progression. Grade A Exercise testing is valuable in Stage C1 patients who claim to be asymptomatic, as unmasking symptoms triggers intervention and a fall in systolic blood pressure of ≥10 mmHg from baseline to peak exercise makes AVR reasonable (ACC/AHA class 2a) at low surgical risk.

Lisinopril (Zestril): Lisinopril 5 mg PO daily, titrate to 10-20 mg daily

Furosemide (Lasix) for volume overload: Furosemide 20-40 mg PO daily PRN

Carvedilol for rate control if concurrent AF: Carvedilol 3.125 mg PO BID, titrate cautiously

Stable / AsymptomaticContinue surveillance: mild AS q3-5yr, moderate q1-2yr, severe asymptomatic (C1) q6-12 months with exercise testing
Symptom Onset or EF DeclineSymptoms develop (dyspnea, syncope, angina), or LVEF drops below 50%, or exercise test abnormal → proceed to Step 2 for valve replacement evaluation
2
Step 2 — Aortic Valve Replacement (Stage C2, D1-D3)

Aortic valve replacement is the definitive treatment for symptomatic severe AS (Stage D) and is recommended for asymptomatic severe AS with reduced LVEF below 50% (Stage C2). Grade A The heart team determines TAVR versus SAVR based on patient-specific factors. For patients under age 65 at low surgical risk, SAVR remains preferred due to superior long-term durability data. For patients over 80 or at high/prohibitive surgical risk (STS-PROM >8%), TAVR is the standard of care. For intermediate-risk patients (STS-PROM 4-8%), both approaches are reasonable; shared decision-making considers anatomy, comorbidities, and valve durability needs. Post-AVR anticoagulation depends on valve type.

Post-bioprosthetic AVR (SAVR or TAVR): Aspirin 81 mg PO daily indefinitely

Post-mechanical AVR anticoagulation: Warfarin (Coumadin) PO daily, target INR 2.5-3.5

Dual antiplatelet post-TAVR (if no anticoagulation indication): Aspirin 81 mg PO daily + Clopidogrel 75 mg PO daily x 3-6 months

Successful AVRSymptom resolution expected within weeks; cardiac rehabilitation; serial TTE at 30 days, 1 year, then annually to assess prosthetic valve function
Not an AVR CandidateProhibitive risk with limited life expectancy <1 year, severe dementia, or patient declines intervention → proceed to Step 3 for palliative strategies
3
Step 3 — Balloon Aortic Valvuloplasty / Palliative Management

Balloon aortic valvuloplasty (BAV) provides transient hemodynamic improvement but is not a definitive therapy due to near-universal restenosis within 6-12 months and no improvement in long-term survival. BAV serves as a bridge to TAVR or SAVR in hemodynamically unstable patients or as a diagnostic trial in patients where the contribution of AS to symptoms is uncertain. For patients who are not candidates for any valve replacement, palliative medical management focuses on symptom relief with careful diuresis, heart failure optimization with neurohormonal blockade as tolerated, and goals-of-care discussions including hospice referral. Grade C

Palliative diuresis: Furosemide 20-80 mg PO daily, titrate to symptoms

Heart failure management if tolerated: Sacubitril-valsartan (Entresto) 24/26 mg PO BID, titrate cautiously

BAV as BridgeHemodynamic improvement allows stabilization for definitive AVR within 2-4 weeks; do not delay definitive intervention
Palliative OnlyComfort-focused care; diuretics for congestion; opioids for refractory dyspnea; hospice referral when appropriate
5
NNT
TAVR vs medical therapy to prevent 1 death at 1yr (high risk)
20
NNH
Permanent pacemaker implantation after TAVR
Absolute Contraindication
Active endocarditis. Severe peripheral vascular disease precluding femoral access for TAVR (consider alternative access). Annular size outside available prosthesis range. Life expectancy less than 12 months from non-cardiac causes.
Relative Contraindication
Bicuspid aortic valve (off-label for many TAVR platforms, though expanding data support use in selected patients). Severe aortic regurgitation. Heavy asymmetric LVOT calcification. Low coronary height (<10 mm) with risk of coronary obstruction.
Aortic Stenosis Treatment Decision Algorithm Decision tree flowchart showing the treatment pathway for aortic stenosis from initial diagnosis through severity assessment, symptom evaluation, surgical risk stratification, and choice between SAVR, TAVR, or palliative management. Severe AS Confirmed (AVA ≤1.0) Symptoms? (HF/Syncope/Angina) No Stage C1: Watch TTE q6-12mo Exercise test EF<50%? Stage C2 → AVR Yes Stage D → AVR Indicated Heart Team Evaluation Surgical Risk? Low (STS<4%) Age <65: SAVR preferred ≥65: TAVR or SAVR High/Prohibitive Life exp >1yr? Yes TAVR No Palliative / BAV Bridge Symptom management only AVR = aortic valve replacement | SAVR = surgical AVR | TAVR = transcatheter AVR STS-PROM = Society of Thoracic Surgeons Predicted Risk of Mortality | BAV = balloon aortic valvuloplasty

Special Populations

Dose adjustments and valve selection considerations for special populations
PopulationDrug / ConsiderationSpecific Recommendation
Renal ImpairmentWarfarin, ACEi, diureticsCrCl <30: reduce lisinopril starting dose to 2.5 mg; furosemide may need higher doses (80-160 mg) for same effect; warfarin sensitivity increased in ESRD. Avoid mechanical valve if possible in dialysis patients due to accelerated valve calcification and bleeding risk
Hepatic ImpairmentWarfarinChild-Pugh B/C: warfarin metabolism reduced via CYP2C9; start at lower dose (2-3 mg daily); INR monitoring twice weekly initially. Bioprosthetic valve preferred to avoid long-term anticoagulation
Elderly (≥80)TAVR vs SAVR selectionTAVR preferred over SAVR for patients ≥80 regardless of STS score; lower perioperative mortality, shorter recovery. Avoid aggressive BP targets (<120 systolic) to prevent hypoperfusion. Frailty assessment (5-meter walk, grip strength) essential for outcomes prediction
PregnancyValve selection, anticoagulationMechanical valve requires warfarin (teratogenic: category X, Dandy-Walker and stippled epiphyses) versus heparin bridging. Bioprosthetic valve avoids anticoagulation but may degenerate faster. Balloon valvuloplasty can temporize critical AS during pregnancy. Ross procedure (pulmonary autograft) optimal for women of childbearing age
Pediatric / Young AdultsBicuspid valve managementBicuspid AS is the most common etiology under age 65. Ross procedure (pulmonary autograft) offers growth potential and no anticoagulation. Mechanical valve with warfarin if Ross not feasible. TAVR generally not appropriate under age 50 due to limited durability data
Concurrent CADCombined CABG + AVRSignificant CAD (LM ≥50%, proximal LAD ≥70%) at time of AVR: combined CABG + SAVR is standard. For TAVR candidates with concurrent CAD, PCI performed before or during TAVR procedure based on anatomic complexity

Drug Interactions

Clinically significant drug interactions in aortic stenosis management
DrugInteracting AgentMechanismClinical EffectManagement
WarfarinAmiodaroneInhibits CYP2C9 and CYP3A4 warfarin metabolismINR increases 30-50% within 1-2 weeks; bleeding risk markedly elevatedReduce warfarin dose by 30-50% when initiating amiodarone; check INR at 3, 7, and 14 days; effect persists weeks after amiodarone discontinuation
WarfarinAspirin / ClopidogrelAdditive antiplatelet effect compounding anticoagulant bleeding riskTriple therapy (warfarin + aspirin + clopidogrel) increases major bleeding 3-foldMinimize duration of triple therapy to 1 month when possible; use PPI gastroprotection; consider rivaroxaban 15 mg + P2Y12 inhibitor without aspirin if AF + recent PCI
ACE inhibitorsPotassium-sparing diuretics / MRAsDual RAAS blockade reduces aldosterone-mediated potassium excretionHyperkalemia risk, especially with CKD (eGFR <45); potentially fatal cardiac arrhythmiaCheck K+ at baseline, 1 week, and 4 weeks after combining; hold if K+ >5.5 mEq/L; avoid combination if eGFR <30
CarvedilolNon-dihydropyridine CCBs (diltiazem, verapamil)Additive negative chronotropy and inotropy via combined beta-blockade and calcium channel blockadeSevere bradycardia, heart block, acute decompensated heart failureAvoid combination in severe AS; if rate control needed, use one agent class only; monitor HR and PR interval on ECG
FurosemideNSAIDs (ibuprofen, naproxen)NSAIDs inhibit renal prostaglandin synthesis, reducing renal blood flow and sodium excretionBlunted diuretic response; fluid retention; accelerated renal dysfunction; risk of acute HF decompensationAvoid NSAIDs in patients with AS and heart failure; use acetaminophen for pain; if NSAID absolutely needed, use lowest dose for shortest duration with Cr/K+ monitoring
Patient Summary

Aortic stenosis is a progressive narrowing of the heart’s aortic valve that forces the heart to work harder to pump blood. In early stages, no treatment is needed beyond monitoring with periodic heart ultrasounds. Once symptoms develop — shortness of breath with activity, fainting, or chest pain — the valve must be replaced either through open-heart surgery (SAVR) or a less invasive catheter-based procedure (TAVR). No medication can stop or reverse valve narrowing. After valve replacement, most patients experience significant symptom improvement and return to normal daily activities within weeks to months.

Stage-based management

Aortic stenosis: surveillance and AVR by stage

Stage B — progressive AS, no symptoms

  • Mild (Vmax 2.0–2.9 m/s): TTE every 3–5 years
  • Moderate (Vmax 3.0–3.9 m/s, mean gradient 20–39 mmHg): TTE every 1–2 years

Stage C1 — severe AS, no symptoms, LVEF ≥50%

  • Vmax ≥4.0 m/s or mean gradient ≥40 mmHg; AVA ≤1.0 cm²
  • TTE every 6–12 months; exercise test while asymptomatic, to unmask latent symptoms
  • Symptoms, LVEF <50%, abnormal exercise test or rapid progression: AVR evaluation

Stage C2 — severe AS, no symptoms, LVEF <50%: AVR recommended

Stage D — severe AS with symptoms (dyspnea, syncope, angina)

  • D1 high gradient; D2 low-flow low-gradient, LVEF <50%; D3 low-flow low-gradient, LVEF ≥50%
  • AVR indicated for all D substages
  • D2: low-dose dobutamine stress echo confirms true severe AS; D3: CT calcium score helps confirm

When AVR is indicated: the heart team chooses SAVR or TAVR

  • Under 65 at low surgical risk: SAVR preferred (durability)
  • Age 65–80: SAVR or TAVR by shared decision-making
  • Over 80 with reasonable anatomy, or STS-PROM >8%: TAVR

Symptomatic severe AS: avoid sublingual nitroglycerin and overdiuresis; prioritize valve intervention.

Not an AVR candidate (prohibitive risk with life expectancy <1 year): palliative strategies.

Aortic stenosis stages B to D and the choice of SAVR or TAVR. Sources: This article (staging, Treatment Algorithm, Commentary, Practice Insights)
4

Monitoring & Surveillance

Monitoring in aortic stenosis serves two distinct purposes depending on the disease stage. In pre-intervention patients, surveillance tracks hemodynamic progression and identifies the optimal window for valve replacement before irreversible myocardial damage occurs. In post-intervention patients, monitoring focuses on prosthetic valve function, detection of structural valve deterioration, paravalvular leak progression, conduction abnormalities, and optimization of antithrombotic therapy. The frequency and intensity of monitoring scale with disease severity and the type of intervention performed. Every patient with known AS, regardless of severity, requires a baseline echocardiogram at diagnosis with serial follow-up intervals determined by the hemodynamic grade. Symptom assessment at every visit is paramount, as symptom onset remains the single most important trigger for intervention referral.

Baseline / Diagnosis
  • TTE: AVA, Vmax, mean gradient, LVEF, LV dimensions, wall thickness, diastolic function (E/e’ ratio)
  • ECG: LVH criteria (Sokolow-Lyon ≥35 mm), conduction disease, AF
  • BNP or NT-proBNP (prognostic stratification)
  • CT calcium score if hemodynamic discordance suspected
  • STS-PROM score calculation if approaching intervention threshold
Every 6–12 Months (Stage C)
  • TTE: repeat hemodynamic assessment (AVA, gradients, LVEF trend)
  • Symptom questionnaire: NYHA class, exertional tolerance, syncope/pre-syncope
  • Exercise stress test if asymptomatic (C1) to unmask latent symptoms
  • BNP trend (rising BNP predicts symptom onset within 12 months)
Post-AVR: 30 Days
  • TTE: prosthetic valve gradients, paravalvular leak assessment, LVEF recovery
  • ECG: new conduction disease (LBBB, high-degree AV block — especially post-TAVR)
  • CBC, Cr, INR (if on warfarin)
  • Wound/access site assessment (femoral for TAVR, sternotomy for SAVR)
Post-AVR: Annual / Long-term
  • TTE annually: prosthetic valve gradients (rising gradient suggests SVD), paravalvular leak stability
  • INR q2-4 weeks (mechanical valve: target 2.5-3.5 aortic position)
  • Endocarditis prophylaxis education (dental procedures, high-risk exposures)
  • Blood cultures if fever >38.0 C persisting >48 hours (prosthetic valve endocarditis screening)

Response & Safety Parameters

Monitoring parameters, targets, and action thresholds for aortic stenosis management
ParameterTarget / ThresholdFrequencyAction if Abnormal
Aortic valve area (pre-intervention)Track rate of decline; AVA ≤1.0 cm2 = severeq6-12mo (severe), q1-2yr (moderate)AVA ≤1.0 with symptoms or EF <50% → immediate heart team referral for AVR
LVEF≥50% (compensated); <50% triggers AVR even if asymptomatic (Stage C2)Every TTEEF decline >10% from baseline or EF <50% → urgent AVR evaluation regardless of symptoms
Mean prosthetic gradient (post-AVR)Bioprosthetic: 10-20 mmHg normal; >20 mmHg concerning for SVD or PPM30 days, 1 year, then annuallyRising gradient >10 mmHg from baseline → CT for leaflet thickening/thrombosis; TEE for detailed assessment
INR (mechanical valve)2.5–3.5 (aortic position)q2-4 weeks once stableINR <2.0 → increase warfarin dose; INR >4.0 → hold dose, recheck in 2 days; INR >9 without bleeding → vitamin K 2.5 mg PO
BNP / NT-proBNPTrending baseline; >3x baseline concerningBaseline, q6-12mo in severe AS, post-AVR 30 daysRising BNP in asymptomatic severe AS → intensify surveillance to q3-6 months; consider exercise testing
Blood pressureSystolic <130 mmHg (avoid <110 in severe AS to prevent hypoperfusion)Every clinic visitSBP >140 → uptitrate ACEi/ARB; SBP <100 with symptoms → reduce or hold antihypertensives, reassess volume status
5

Clinical Commentary

Clinical Pearl
The classic teaching that ACE inhibitors are “contraindicated” in aortic stenosis is outdated and oversimplified. In reality, ACE inhibitors and ARBs are well-tolerated in most patients with compensated AS and concurrent hypertension. The concern about preload reduction causing hypotension applies primarily to patients with decompensated heart failure and fixed low cardiac output. Start at low doses (lisinopril 2.5-5 mg) and titrate gradually with blood pressure monitoring. Uncontrolled hypertension in AS patients actually increases afterload beyond the fixed valvular obstruction, doubling the hemodynamic burden on the left ventricle and accelerating decompensation.
Clinical Pearl
When evaluating a patient with severe AS and discordant echocardiographic parameters (e.g., AVA 0.8 cm2 but mean gradient only 28 mmHg), do not reflexively downgrade the severity to “moderate.” First check the stroke volume index: if SVi is below 35 mL/m2, the patient has low-flow physiology that explains the discordance. Measure the dimensionless index (velocity ratio): if less than 0.25, the stenosis is severe regardless of the absolute gradient. Consider CT calcium scoring as the tiebreaker. Missing paradoxical low-flow low-gradient severe AS (Stage D3) is one of the most common diagnostic errors in valvular heart disease, and these patients have outcomes as poor as classical high-gradient severe AS if left untreated.
Common Pitfall
Prescribing nitrates or aggressive diuresis in symptomatic severe aortic stenosis without concurrent heart team evaluation. The instinct to treat dyspnea with furosemide or angina with nitroglycerin is reasonable in most cardiac patients but dangerous in severe AS. Nitrates cause venodilation that reduces preload to a ventricle that depends on adequate filling pressure to maintain cardiac output across the fixed obstruction. The result can be profound hypotension and syncope, sometimes progressing to cardiovascular collapse. Similarly, overdiuresis reduces preload and can trigger hypotension that is refractory to fluid resuscitation because the fixed obstruction limits the ability to augment stroke volume. Use the lowest effective diuretic dose, avoid sublingual nitroglycerin, and prioritize valve intervention rather than prolonged medical temporization.
Common Pitfall
Delaying referral for valve replacement in patients with severe AS who are “doing well” on medical therapy. There is no effective medical therapy for aortic stenosis, and clinical stability is deceptive. Once the aortic valve area reaches the severe range, patients are in a window where intervention has the best outcomes because the left ventricle has not yet undergone irreversible fibrotic remodeling. Every month of delay with severe symptomatic AS increases the risk of sudden cardiac death (estimated 1-2% per year even in asymptomatic severe AS). The moment any of the classic symptoms appear, valve replacement should be pursued without delay. Waiting for symptoms to become “severe enough” is a dangerous practice that leads to worse post-operative outcomes and higher perioperative mortality.
High-Alert Drug Warning
Warfarin (post-mechanical aortic valve replacement): Narrow therapeutic index requiring meticulous INR monitoring. Subtherapeutic INR (<2.5 for aortic mechanical valve) risks catastrophic valve thrombosis with hemodynamic collapse. Supratherapeutic INR (>4.0) risks life-threatening hemorrhage. Required monitoring: INR twice weekly during initiation, then every 2-4 weeks once stable. Numerous drug and food interactions (vitamin K-containing foods, amiodarone, antibiotics, antifungals). Genetic polymorphisms in CYP2C9 and VKORC1 affect dosing requirements. Patients must carry anticoagulant alert identification at all times. Reversal agents: vitamin K 2.5-10 mg PO/IV for non-urgent reversal; 4-factor PCC (25-50 units/kg IV) for life-threatening bleeding.
When to Refer
Urgent cardiology / heart team referral: (1) Any patient with echocardiographically severe AS (AVA ≤1.0 cm2, Vmax ≥4.0 m/s) who develops new symptoms (dyspnea NYHA II+, exertional syncope, or angina) → valve replacement evaluation within 2 weeks. (2) Asymptomatic severe AS with LVEF decline below 50% on serial TTE (Stage C2) → AVR recommended even without symptoms. (3) Severe AS with rapid hemodynamic progression (mean gradient increase >7 mmHg/year or Vmax increase >0.3 m/s/year) → intensified surveillance and early heart team discussion.

Emergency / inpatient transfer: (4) Acute decompensated heart failure with known severe AS → hospital admission; IV diuresis with hemodynamic monitoring; urgent echocardiography; consider intra-aortic balloon pump or percutaneous LVAD if cardiogenic shock; balloon valvuloplasty as bridge to definitive AVR. (5) Syncope with known severe AS → admit for continuous telemetry; rule out ventricular arrhythmia and complete heart block; avoid vasodilators; expedite AVR evaluation. (6) Suspected prosthetic valve endocarditis (persistent fever, new regurgitant murmur, embolic phenomena) → blood cultures x3, TEE, infectious disease consultation, cardiac surgery standby.
Areas of Uncertainty
  • Optimal timing of intervention in asymptomatic severe AS (Stage C1) with preserved LVEF remains debated; early AVR trials (AVATAR, RECOVERY) suggest benefit but practice guidelines still favor watchful waiting with close surveillance C
  • Long-term durability of TAVR beyond 10-15 years is unknown, making the choice between TAVR and SAVR in patients aged 50-65 particularly challenging
  • The role of lipoprotein(a)-lowering therapies (e.g., pelacarsen) in slowing calcific aortic valve disease progression is under active investigation but remains unproven
  • Whether subclinical leaflet thrombosis detected on CT after TAVR requires anticoagulation treatment or represents a benign finding is unresolved

Practice Insights: What Drives AS Timing and Modality Choices

(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.)On structural-heart and cardiology services, aortic stenosis is the field where the past five years have fundamentally rewritten the treatment paradigm — TAVR has expanded from elderly high-risk patients to become the preferred modality across the age and risk spectrum in the right anatomy, and the severe asymptomatic AS surveillance window has tightened with exercise stress testing routinely uncovering subclinical symptoms that anchor earlier intervention.

What the Guideline Misses

The TAVR-versus-SAVR decision is now equivalent in low-risk patients with appropriate anatomy, not just an option for elderly high-risk candidates. PARTNER-3 and Evolut Low Risk trials demonstrated non-inferior outcomes for TAVR in low-risk patients, and the 2024 AHA/ACC guidelines reflect this paradigm shift. Practice has moved toward TAVR as preferred modality in patients age 80 and older with reasonable anatomy, shared decision-making in age 65-80, and SAVR preferred under 65 unless bioprosthetic valve and anatomical considerations argue otherwise. The “TAVR only if too high-risk for surgery” framing is outdated.

Patterns That Recur

Severe asymptomatic aortic stenosis monitored too passively without exercise stress testing is the practice gap most often needing correction in referrals. The patient self-reporting “no symptoms” on history may have measurable functional limitation on graded exercise testing — modified Bruce protocol with monitoring for blood pressure response, ST changes, arrhythmia, and exertional dyspnea. Symptom development at low exercise threshold reclassifies the patient as functionally symptomatic and shifts the treatment paradigm toward intervention. In apparently asymptomatic severe AS (Stage C1) at low surgical risk, AVR is reasonable (ACC/AHA class 2a) when the exercise test shows decreased exercise tolerance (normalized for age and sex) or a fall in systolic BP of 10 mmHg or more from baseline to peak exercise; management of a lack of appropriate BP rise is less clear.

A Bedside Heuristic

Severe AS is defined by any of three echocardiographic criteria: peak aortic velocity 4 m/s or greater, mean transvalvular gradient 40 mmHg or greater, or aortic valve area 1.0 cm² or less. Severe AS plus symptoms (dyspnea, angina, syncope) is class I indication for valve replacement. Severe asymptomatic AS with reduced LVEF under 50%, abnormal exercise test, BNP elevation, or rapid progression also warrants intervention. The classical “watch and wait” approach for severe asymptomatic disease is being replaced by earlier intervention in selected populations.

Post-TAVR Conduction Monitoring

Post-TAVR permanent pacemaker requirement in 10-15% of patients (higher with self-expanding valves and pre-existing right bundle branch block) is the under-counseled complication. Pre-procedural ECG review with attention to baseline conduction abnormalities, RBBB documentation, and patient counseling about the pacemaker risk improves informed consent. Post-procedural telemetry monitoring for at least 24-48 hours, with daily ECG comparison, captures the delayed conduction blocks that present 1-7 days post-implantation.

Illustrative Scenario

A woman in her late seventies presented with progressive exertional dyspnea over 6 months and one episode of syncope on exertion. Transthoracic echocardiogram demonstrated severe aortic stenosis with peak velocity 4.6 m/s, mean gradient 52 mmHg, aortic valve area 0.7 cm², and preserved left ventricular ejection fraction 58%. AHA/ACC stage D (severe symptomatic AS) was met. STS surgical risk score was 6.5% (intermediate risk), and she preferred transcatheter approach after multidisciplinary heart team consultation. Pre-procedural CT confirmed adequate transfemoral access vessels, suitable annular dimensions, and no significant coronary disease requiring concurrent revascularization. Balloon-expandable TAVR was performed via right transfemoral approach with successful valve deployment, mean gradient post-implant 8 mmHg, mild paravalvular leak. Post-procedural telemetry on hospital day 2 showed new persistent complete heart block in the setting of pre-existing left bundle branch block. Permanent pacemaker was placed on hospital day 5 prior to discharge. She was discharged on hospital day 7 with NYHA functional class I at 6-week follow-up and continued improvement at 12-month follow-up with stable valve function on surveillance echo.

The takeaway: pre-procedural conduction assessment plus extended post-procedural telemetry plus appropriate pre-procedural counseling about pacemaker risk prepares both patient and team for the 10-15% pacemaker requirement that complicates TAVR. The procedure remains the right choice but the counseling cannot be afterthought.

Protocol Adjustments to the Standard Pathway

  1. TAVR-versus-SAVR shared decision-making across the age spectrum, not just elderly or high-risk patients. Age 80+ with reasonable anatomy = TAVR preferred. Age 65-80 = shared decision-making. Age under 65 = SAVR usually preferred unless bioprosthetic and access considerations favor TAVR. PARTNER-3 and Evolut Low Risk evidence supports this paradigm shift.
  2. Exercise stress testing for severe asymptomatic AS to unmask subclinical functional limitation. Modified Bruce protocol with BP response monitoring, ST changes, arrhythmia, exertional dyspnea or pre-syncope. Symptoms provoked on exercise testing reclassify the patient as symptomatic (AVR indicated); in Stage C1 at low surgical risk, decreased exercise tolerance (normalized for age and sex) or a fall in systolic BP of 10 mmHg or more from baseline to peak exercise makes AVR reasonable (ACC/AHA class 2a), while management of a lack of appropriate BP rise is less clear.
  3. Pre-procedural conduction assessment plus extended post-TAVR telemetry 24-48 hours minimum, with daily ECG comparison. Permanent pacemaker requirement in 10-15% post-TAVR is the under-counseled complication that benefits from explicit pre-procedural informed consent.
  4. Severe asymptomatic AS with reduced LVEF under 50%, abnormal exercise test, BNP elevation, or rapid progression warrants intervention, rather than indefinite “watchful waiting.” Early intervention in selected severe asymptomatic patients is supported by emerging evidence.
6

Frequently Asked Questions

How do you differentiate low-flow low-gradient severe AS from moderate AS in a patient with reduced ejection fraction?
Perform a low-dose dobutamine stress echocardiogram starting at 5 mcg/kg/min and titrating to 20 mcg/kg/min. True severe AS demonstrates an aortic valve area that remains 1.0 cm2 or less with a rise in mean gradient to 40 mmHg or more as stroke volume increases. Pseudo-severe AS shows valve area opening beyond 1.0 cm2 with improved flow. Failure of stroke volume to increase by at least 20% indicates lack of contractile reserve and portends worse surgical outcomes.
When should you choose TAVR over surgical AVR for a patient with symptomatic severe aortic stenosis?
TAVR is the preferred approach for patients at prohibitive or high surgical risk as determined by the heart team using STS-PROM score greater than 8% or clinical frailty indicators. For intermediate-risk patients with STS-PROM 4-8%, both TAVR and SAVR are reasonable and the decision should incorporate anatomic factors such as bicuspid valve morphology, coronary access, and annular size. For low-risk patients under age 65, SAVR remains preferred due to superior long-term durability data beyond 10 years and lower rates of paravalvular leak and permanent pacemaker implantation.
Is there any medical therapy that slows the progression of calcific aortic stenosis?
No pharmacologic therapy has demonstrated the ability to slow, halt, or reverse calcific aortic valve disease. Multiple randomized trials including SALTIRE, SEAS, and ASTRONOMER showed that statin therapy does not reduce the rate of hemodynamic progression or delay the need for aortic valve replacement despite lowering LDL cholesterol. Current management focuses on treating concurrent cardiovascular risk factors, optimizing blood pressure, managing heart failure symptoms, and pursuing timely valve intervention once indications are met.
gomdori Medical — Aortic Stenosis: Diagnosis, Staging, and Management
Last updated: April 12, 2026 gomdorimedical.com
Related clinical topics
More in Cardiovascular Medicine
  • Aortic Regurgitation: ACC/AHA Diagnosis, Echo Severity Grading, and Surgical Timing
  • Mitral Stenosis: ACC/AHA 2020 Severity Staging, Wilkins Score, and PMBV vs Surgical Replacement
  • Atrial Fibrillation — Diagnosis and Comprehensive Management
  • Hypertension — Diagnosis, Risk Stratification, and Pharmacotherapy
  • Stable Ischemic Heart Disease: Diagnosis and Optimal Medical Therapy
  • Acute and Recurrent Pericarditis: Diagnosis and Treatment
Posted in Cardiovascular MedicineTagged aortic stenosis, aortic valve replacement, cardiology, echocardiography, heart failure, left ventricular hypertrophy, SAVR, TAVR, valve calcification, valvular heart disease

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

61 free tools

Endoscopy Findings Atlas · Explore endoscopic findings and diagnostic distinctions.

Health & clinical tools

Find personal records, research helpers and clinical references.

  • Personal Records & Visits11 tools
  • Measurements & Conversions3 tools
  • Research & Events11 tools
  • Clinical Scores & Tests16 tools
  • Medication & Treatment References14 tools
  • Screening & Procedures6 tools
Browse all 61 tools →

Clinical references are for qualified professionals. Check each tool’s scope and limitations.

Tools to try
  • AUDIT-C Alcohol Screening & Unit Calculator
  • Acute Pancreatitis Severity Calculator
  • Ascites SAAG & SBP Diagnostic Assistant
Support This Project
Help keep medical education free
Donate via PayPal

Recent Posts

  • Recurrent Pericarditis: Colchicine, Rilonacept, Anakinra, and Steroid-Sparing IL-1 Blockade
  • Charles Bonnet Syndrome: Visual Release Hallucinations in Acquired Vision Loss Reassurance and Cognitive Coping Strategies
  • PCOS Endocrine Workup: Rotterdam Criteria, Hyperandrogenism Differential, and Long-Term Metabolic Surveillance
  • Crohn’s Disease — Diagnosis, Montreal Classification, and Therapy
  • PAPA Syndrome: PSTPIP1 Autoinflammatory Disease with Pyogenic Sterile Arthritis Pyoderma Gangrenosum and Cystic Acne

Categories

  • Allergy & Clinical Immunology
  • Cardiovascular Medicine
  • Clinical Nutrition
  • Clinical Pharmacology
  • Critical Care Medicine
  • Dermatology
  • Emergency Medicine
  • Endocrinology & Metabolism
  • Gastroenterology
  • General Surgery
  • Geriatric Medicine
  • Hematology & Blood Disorders
  • Infectious Diseases
  • Medical Genetics
  • Nephrology & Renal Care
  • Neurology
  • Obstetrics & Gynecology
  • Occupational & Environmental Medicine
  • Oncology & Cancer Care
  • Ophthalmology
  • Order Sets
  • Orthopedics & Sports Medicine
  • Otolaryngology
  • Pain Medicine
  • Palliative Care
  • Pediatrics
  • Procedures
  • Psychiatry
  • Radiology
  • Respiratory Medicine
  • Rheumatology
  • Sleep Medicine
  • Urology
  • Vaccines & Preventive Medicine

Medical Disclaimer

This content is for educational and informational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider for clinical decision-making. The author assumes no liability for actions taken based on this content.

GM

Gomdori, MD

Gastroenterologist · Medical educator

A practising gastroenterologist in South Korea writing bedside-focused clinical education — guideline-derived, dose-precise, and aimed at the decision in front of you rather than the exam question.

Writes about

Gastroenterology & hepatologyEndoscopyGuideline appraisal

Editorial standard

  • Every figure is traced to a primary source and dated
  • Corrections are made on request — not quietly
  • Unverifiable data is omitted, never estimated
About the author Corrections

gomdori Medical

Evidence-based medical education by a practicing gastroenterologist in South Korea. Free clinical content for physicians, residents, and medical students.

Learn more →

Quick Links

  • Gastroenterology
  • Procedures
  • Critical Care
  • About
  • Medical Disclaimer

Contact

Corrections, topic requests, and feedback are always welcome.

gomdoridoctor@gmail.com

Support via PayPal

© 2026 gomdori Medical. All rights reserved.

Content is for educational purposes only and does not constitute medical advice. Full disclaimer

Built with clinical expertise & programmatic precision.

AboutToolsPrivacy PolicyTerms of UseEditorial PolicyDisclaimerContact
Free tools →

© 2026 Gomdori Medical. Educational content only — not professional advice. Figures are dated at the point of publication and change over time; verify against the original source before acting on them.

AboutToolsPrivacy PolicyTerms of UseDisclaimerContact
Free tools →

© 2026 Gomdori Medical. Educational content only — not professional advice. Figures are dated at the point of publication and change over time; verify against the original source before acting on them.

Copyright © 2026 Gomdori Medical – OnePress theme by FameThemes